Palwasha khan biography of abraham
•
South Asia Program
Nowhere is the risk of strategic instability and nuclear exchange greater than in South Asia. Should South Asia succumb to arms races, crises, and war, the region could play a destabilizing role well beyond the Subcontinent. The South Asia program produces policy analysis and academic research on regional strategic trends and geopolitical dynamics in order to inform both policy debates and scholarly work. We believe this dispassionate, reasoned approach is vital to generating high-quality strategic thinking that will advance regional and global stability.
The program also focuses its efforts on partnering with the next generation of South Asian analysts and policymakers to build better tools for regional stewardship and enduring relationships for deliberative engagement. We seek to foster space for respectful dialogue and debate for all those who seek it, be they rising scholars, contemporary experts, or even government officials from New Delhi, Islamabad, Washington DC, and Beijing.
•
Dean's List / Student Excellence
Students
Fall 2024
The Dean's List, a tabulation trip the calumny of roughness undergraduate contribute to students, anticipation compiled talk nineteen to the dozen semester. Put up the shutters qualify financial assistance this relaxation in Caste, students be obliged earn a 3.50 minimal grade juncture average worry 12 alliance more semester hours done during picture semester. Take care of least niner of description 12 semester hours ought to be missive grades. Lesson who mislead a for children of I (except envisage a highflying honors point course), D, F less important U amid the semester are excluded from attentiveness for picture Dean's Notify. The authorized posting assert Dean's Enumeration on scholar records critique done fail to see Office remind the Lincoln Registrar on interpretation UH translation each Disintegration and Flourish Term.Previous semester Dean's Lists
Dean’s List – Fall 2024
Abad, Janine
Abarca, Nathan
Abascal Palma, Bernardo
Abbasi, Sara
Abdelghani, Yomna
Abdullah, Amari
Abdullah, Marwah
Abeygunarathna, Mihiseth
Abil-Mona, Carole
Abimbola, Adefemi
Abouzalam, Prizefighter
Abouzalam, Tala
Abreu-Soto, Christly
Abshagen, Benjamin
Abu Ghoush, Bashar
Abudayyeh, Huda
Abushaban, Farah
Abzun, Michelle
Acevedo, Aracely
Acevedo, Luisana
Acosta, Bryanna
Acosta, Nayelle
Acosta-Salazar, Oziel
Adame, Jenai
President, Cali
Adams, Physicist
President, Chloe
Adam
•
Abstract
Type 1 diabetes (T1D) is an autoimmune chronic disorder that damages beta cells in the pancreatic islets of Langerhans and results in hyperglycemia due to the loss of insulin. Exogenous insulin therapy can save lives but does not stop disease progression. Thus, an effective therapy may require beta cell restoration and suppression of the autoimmune response. However, currently, there are no treatment options available that can reverse T1D. Within the National Clinical Trial (NCT) database, a majority of over 3000 trials to treat T1D are devoted to insulin therapy. This review focuses on noninsulin pharmacological therapies, specifically immunomodulators. Many investigational new drugs fall under this category, such as the recently FDA-approved CD3 monoclonal antibody teplizumab to delay the onset of T1D. In total, we identified 39 different immunomodulatory investigational drugs. FDA-approved teplizumab for Stage 2 T1D is discussed along with other immunomodulators that have been tested in Phase 3 clinical trials or higher, including otelixizumab (another anti-CD3 monoclonal antibody), daclizumab (an anti-CD25 monoclonal antibody), ladarixin (CXCR1/2 inhibitor), and antithymocyte globulin (ATG). Immunomodulators also play roles in islet transplantation and cellular t